Cencora Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.1%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$337.1Bnext fiscal year
FY EPS (est.)
$17.87next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. Healthcare Solutions Segment Operating Income Growth Quarterly21.0%Target: 14% to 16% for Fiscal 2026
Consolidated Adjusted Operating Income Growth Quarterly11.9%Target: 11.5% to 13.5% for Fiscal 2026
Consolidated Revenue Growth Quarterly3.9%Target: 4% to 6% for Fiscal 2026
Watch Items
- Specialty drug volume softness and oncology utilization decelerationTrigger: Sustained deceleration in oncology utilization or IQVIA specialty volume data weaknessAction: Re-evaluate U.S. segment operating income growth targets and adjust MSO platform contribution models.
- GLP-1 related demand momentum and brand conversionsTrigger: Slowing momentum in GLP-1 demand or lower sales to large mail-order customers due to brand conversionsAction: Assess impact on gross profit margins and adjust full-year revenue outlook.
- Integration of OneOncology and Retina Consultants of America (RCA)Trigger: Weaker-than-expected operating margins or integration delays in the MSO platformAction: Review vertical integration synergies, clinical research, and revenue cycle management performance.
Research as of 2 Sep 2026